Monitor for future announcements regarding clinical trial initiation in the U.S. or Europe, which could serve as a catalyst. Without revenue or guidance data, this filing alone does not provide a trading signal.
Price Chart
Executive Summary
Optimi Health Corp. announced completion of a GMP production run of 5mg psilocybin capsules, the same formulation already prescribed commercially for treatment-resistant depression in Australia. Additional product from this run is earmarked for planned clinical trials in the U.S. and Europe. The filing is a routine operational update with no financial data, and the forward-looking statements about future trials and market expansion are not backed by concrete milestones or revenue figures.
Key Facts
- Completed GMP production run of 5mg psilocybin finished drug product.
- Same formulation already prescribed commercially in Australia for treatment-resistant depression.
- Additional product earmarked for planned clinical trials in the U.S. and Europe.
- All manufacturing stages completed in-house under Health Canada Drug Establishment Licence.
- Facility includes a Health Canada compliant Level 8 vault with capacity to store controlled substances valued at up to C$100 million.
- Authorized to hold up to 20 kg of psilocybin and approximately 2,000 kg of biomass on site.
Financial Impact
No financial figures disclosed; no revenue, deal value, or offering size provided.
Risk Factors
- Forward-looking statements about clinical trials and market expansion are subject to regulatory approvals and may not materialize.
- No financial data provided; commercial revenue from Australia is not quantified.
- Psychedelic drug sector remains highly regulated and speculative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-252513 |
| Document: d113735d6k.htm | 0001193125-26-252513 |
| Document: 0001193125-26-252513-index-headers.html | 0001193125-26-252513 |
| Document: 0001193125-26-252513-index.html | 0001193125-26-252513 |
| Document: 0001193125-26-252513.txt | 0001193125-26-252513 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.26 (−2.84%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.26 (−2.84%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.26 (−19.19%) |
Oct 5, 2026 20d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.26 (−20.95%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.26 (−31.70%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.26 (−34.18%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.26 (−34.18%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.26 (−33.38%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.26 (−27.45%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.26 (+33.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers